Fineline Cube

Follow:
14483 Articles
Shanghai Juncell Therapeutics has announced that the National Medical Products Administration's Center for Drug Evaluation (CDE) has approved the first pivotal Phase II registration clinical trial for its GC101 TIL injection. The trial, designated as NCT06703398, is for the treatment of advanced melanoma patients who have progressed or are intolerant to PD-1 antibody therapy. The study will be led by Professor Guo Jun, a global authority in melanoma treatment at Beijing Cancer Hospital, and will be conducted as a multicenter clinical research across China.
CompanyDrug

Shanghai Juncell Therapeutics’ GC101 TIL Therapy Receives CDE Approval for Pivotal Phase II Trial

AI Proteins Partners with Bristol Myers Squibb to Develop Miniprotein-Based Therapeutics
CompanyDeals

AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics

Novatim Immune Therapeutics' Y-0301 Receives FDA Clearance for Clinical Trials
CompanyDrug

Novatim Immune Therapeutics’ Y-0301 Receives FDA Clearance for Clinical Trials

NMPA Releases 85th Batch of Reference Drugs for Generic Quality Consistency Evaluation
Policy / Regulatory

NMPA Releases 85th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Hangzhou-Based HighField Biopharmaceutical Advances HF50 for HER-2 Tumors with NMPA Approval
CompanyDrug

HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors

Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment
CompanyDrug

Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment

Chongqing Zhifei Biological and GlaxoSmithKline Amend Distribution Agreement for Herpes Vaccine
CompanyDeals

Chongqing Zhifei Biological and GlaxoSmithKline Amend Distribution Agreement for Herpes Vaccine

GSK plc Partners with Muna Therapeutics to Discover Alzheimer’s Disease Treatment Targets
CompanyDeals

GSK plc Partners with Muna Therapeutics to Discover Alzheimer’s Disease Treatment Targets

Jiangsu Hengrui's SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma
CompanyDrug

Jiangsu Hengrui’s SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma

Roche's Columvi Supplemental sBLA Accepted by FDA for Relapsed DLBCL Treatment
CompanyDrug

Roche’s Columvi Supplemental sBLA Accepted by FDA for Relapsed DLBCL Treatment

Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI
CompanyDrug

Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI

Eyebright Medical Technology Aims to Raise RMB 300 Million for Contact Lens Production Expansion
CompanyDeals

Eyebright Medical Technology Aims to Raise RMB 300 Million for Contact Lens Production Expansion